Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis Amlitelimab, dosed every four weeks or every 12 weeks, ...

NEW HAVEN, Conn. (WTNH) — News 8 is your local election headquarters, and voting took place Tuesday in 21 communities across Connecticut. Two key races News 8 is watching are the Democratic mayoral ...

Munich [Germany], September 1 (ANI): Tamil Nadu government has inked "key MoUs" with German firms during Tamil Nadu Chief Minister MK Stalin's visit to the country as part of his two-nation tour, with ...

CLEVELAND — Voters across Cleveland cast their ballots Tuesday night in a municipal primary that will help determine key leadership roles that could shape the city's immediate future and send ripple ...

Positive results from the global COAST 1 phase 3 study (clinical study identifier: NCT06130566) showed that amlitelimab, a fully human non-T cell depleting monoclonal antibody that targets OX40-ligand ...

CHENNAI: Union Minister of State for Law and Parliamentary affairs, Arjun Ram Meghwal, speaking at the 16th annual convocation ceremony of the Vels Institute of Science, Technology and Advanced ...

Tamil Nadu’s Minister for Health and Family Welfare, Ma.Subramanian has written to Union Minister of Civil Aviation pointing out the challenges faced by air travelers in the state. In a detailed ...

Enlicitide is the first oral PCSK9 inhibitor to demonstrate statistically significant and clinically meaningful reductions in LDL-C compared to placebo in Phase 3 trials RAHWAY, N.J.--(BUSINESS WIRE)- ...

Merck, known as MSD outside of the United States and Canada, announced positive topline results from the phase 3 CORALreef Lipids trial evaluating the safety and efficacy of enlicitide decanoate, an ...

At a media roundtable convened by the Tamil Nadu Food Safety and Drug Administration Department in Chennai on Thursday (September 4, 2025), experts highlighted the growing need to tackle ‘hidden ...